Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Rating of “Moderate Buy” by Analysts

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) have received a consensus recommendation of “Moderate Buy” from the fourteen ratings firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $13.3636.

A number of research analysts have commented on CMPX shares. Wall Street Zen upgraded shares of Compass Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, February 16th. Citizens Jmp set a $10.00 price target on Compass Therapeutics in a research report on Wednesday, December 3rd. William Blair began coverage on Compass Therapeutics in a research note on Monday, January 5th. They set an “outperform” rating for the company. Cantor Fitzgerald started coverage on Compass Therapeutics in a report on Wednesday, December 3rd. They issued an “overweight” rating on the stock. Finally, Leerink Partners raised Compass Therapeutics to a “strong-buy” rating in a report on Wednesday, November 26th.

Compass Therapeutics Price Performance

NASDAQ CMPX opened at $6.17 on Friday. The company has a fifty day moving average of $5.78 and a two-hundred day moving average of $4.60. The company has a market capitalization of $1.10 billion, a PE ratio of -13.71 and a beta of 1.46. Compass Therapeutics has a 1 year low of $1.33 and a 1 year high of $6.88.

Institutional Trading of Compass Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CMPX. Vivo Capital LLC increased its stake in shares of Compass Therapeutics by 70.0% in the second quarter. Vivo Capital LLC now owns 6,043,466 shares of the company’s stock valued at $15,713,000 after purchasing an additional 2,487,443 shares during the period. Tema Etfs LLC bought a new position in Compass Therapeutics in the 4th quarter worth approximately $538,000. Avanza Fonder AB acquired a new stake in Compass Therapeutics in the 4th quarter valued at approximately $147,000. Caxton Corp raised its stake in Compass Therapeutics by 23.1% during the 3rd quarter. Caxton Corp now owns 53,503 shares of the company’s stock valued at $187,000 after acquiring an additional 10,038 shares in the last quarter. Finally, Suvretta Capital Management LLC raised its stake in Compass Therapeutics by 97.2% during the 3rd quarter. Suvretta Capital Management LLC now owns 14,101,159 shares of the company’s stock valued at $49,354,000 after acquiring an additional 6,951,666 shares in the last quarter. Hedge funds and other institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.